Beta Drugs LtdQ1 FY24Pharmaceuticals & Biotechnology

Beta Drugs Ltd

Q1 FY24 Earnings Call Analysis

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Order

N/A

Capex

Yes

1 of 4 growth signals are positive — mixed outlook.

Revenue guidance

Category 2

→Company expects a sales growth of 25%-30% for FY25, continuing previous growth trends.
→Oncology segment projected to grow to Rs. 450-500 crores within 2 years.
→Cosmetology/dermatology segment aims to reach Rs. 30-40 crores in revenue in next 3-5 years, starting from Rs. 1 crore sales in April FY24 and targeting Rs. 14-15 crores in FY24-25.
→Exports expected to increase significantly, targeting 35% of total business volume over next 2-3 years with focus on regulated markets like Colombia, Mexico, Brazil, and Southeast Asia.
→Company plans to increase number of SKUs in cosmetology from current 14 to 40-50 by FY25.
→CAPEX of Rs. 30-35 crores planned over next 2 years (internal accrual-funded) mainly for cosmetology plant (to start FY26) and acquiring marketing authorizations post EU GMP audit.
→Overall strategy focuses on brand creation, sales, profitability, and migration to Mainboard within 2 months to improve visibility and liquidity.

Category 3

→Beta Drugs aims to sustain a sales growth rate of 25% to 30% for FY25 and beyond.
→The company plans to improve EBITDA margins to 24%-26% in FY24-25, after a decline due to high platins raw material costs and cosmetology division losses.
→Oncology segment EBITDA margin stands at 22.8%, excluding cosmetology losses, with a focus on boosting profitability by shifting focus from platins to other products.
→Cosmetology division, currently marginally profitable with Rs. 1 crore sales, targets Rs. 14-15 crore sales in FY24-25, with long-term brand-building potential.
→Exports are targeted to grow significantly, expected to contribute around 35% of total revenue in future years with higher margins in regulated markets.
→Management assures delivering consistent growth and profitability over the next 3-5 years with a focus on innovative oncology products and expanding dermatology and cosmetology offerings.

Get access to all 5 sections — revenue, margin, fundraise, orderbook, and capex — for Beta Drugs Ltd and 1,400+ other companies.

→No current or immediate plans for fundraising through debt or equity were mentioned.
→Rahul Batra stated that for reaching the target of Rs. 450-500 crores revenue, the company does not require any external funds.
→Planned CAPEX of Rs. 30-35 crores over the next 2 years will be funded entirely through internal cash accruals.
→Focus is on internal growth, business operations, and migrating to the Mainboard without involving fundraising activities.
→No discussions have been held regarding share split or issuing bonus shares to improve liquidity; the focus remains on business growth and Mainboard migration.

→The transcript does not explicitly mention specific figures or details about the current or expected order book or pending orders for Beta Drugs Limited.
→The management highlights ongoing efforts including 350+ dossiers filed for regulatory approvals, with business expected to flow in the next year.
→They mention participation in bulk purchase tenders (e.g., Tata Memorial Hospital), expecting to get a share of such orders, potentially benefiting the company.
→The company is focusing on product launches, including 6 new NDDS approvals expected between October and March, likely boosting future sales.
→The management projects 25%-30% sales growth for FY25, indicating a positive outlook on order inflows.
→No direct or explicit data on the order book size or pending orders is provided in the available transcript.

Yes

→Total planned CAPEX for the next 2 years: Rs. 30-35 crores, funded through internal cash accruals.
→Major CAPEX focus on setting up a cosmetology manufacturing plant by FY26 to expand SKUs from 14 to 40-50.
→Additional CAPEX expected for acquiring marketing authorizations (MAs) post-EU GMP audit to speed up product launches in regulated markets.
→No further oncology capacity expansion planned until sales reach Rs. 500 crores; investments will instead focus on MA acquisitions.
→Expansion includes increasing efforts in dermatology and cosmetology manufacturing facilities.
→CAPEX related to asset purchase mainly involves marketing authorizations for faster market entry rather than machinery.
→Current cosmetology CAPEX estimated around Rs. 30-35 crores.

How does Beta Drugs Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Beta Drugs Ltd

Rev 2Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Beta Drugs Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.